Shares of Cipla Limited were trading lower on Friday morning, falling 1.27 per cent to ₹1,289.30 on the NSE by 10.12 AM, even as the pharmaceutical major announced a significant regulatory win in the United States. The stock opened at ₹1,295, touched a high of ₹1,295 and a low of ₹1,254.10, with total traded value crossing ₹217 crore on volumes of 17.06 lakh shares. Buy orders accounted for 54 per cent of total quantity against 46 per cent on the sell side.
The broader context weighs on the stock — Cipla is down 14.36 per cent year-to-date and 17.17 per cent over the past year, significantly underperforming the Nifty 50, which has lost 1.21 per cent in the same period. The 52-week high stands at ₹1,673, hit in October 2025, while the 52-week low of ₹1,165.70 was recorded just weeks ago on April 2.
Morgan Stanley maintained its Underweight rating on the stock, nudging its price target marginally higher to ₹1,237 from ₹1,211. The brokerage pegged the US FDA approval for generic Ventolin HFA at $130 million in FY27 sales potential, estimating a 4 per cent EPS boost. It noted the approval would help offset erosion in Lanreotide sales and strengthen Cipla’s respiratory franchise, but flagged continued dependence on pipeline execution as a key risk.
The trigger for market attention was Cipla USA Inc.’s receipt of final USFDA approval for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation — the first AB-rated generic of GlaxoSmithKline’s Ventolin HFA. The product targets a US albuterol market valued at approximately $1.5 billion and is expected to launch in the first half of FY2026-27. It will be manufactured at Cipla’s dedicated inhalation facility in Fall River, Massachusetts.